Early Detection Research Network

ACBP

Aliases:
This biomarker is also known as:
  • ACBP,
  • GABA Receptor Modulator,
  • Endozepine,
  • Diazepam-Binding Inhibitor,
  • Cholecystokinin-Releasing Peptide, Trypsin-Sensitive,
  • endozepine,
  • ACBD1,
  • Acyl-Coenzyme A Binding Domain Containing 1,
  • EP,
  • diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein),
  • CCK-RP,
  • DBI,
  • Acyl-CoA-Binding Protein,

Description…

DBI, diazepam binding inhibitor, was previously known as ACBP, acyl-coA binding protein. This protein is regulated by hormones, is involved in lipid metabolism, and is thought to act as a neuropeptide to regulate the action of the GABA receptor. DBI is conserved across species. The most highly conserved domain is the hydrophobic binding site for medium- and long-chain acyl-coA esters. DBI is involved in the regulation of pancreatic secretion and release of cholecystokinin. There are three pseudogenes for DBI on separate chromosomes. DBI has multiple transcript variants encoding different isoforms.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
Type: Protein
HGNC Name: DBI

The following organs have data associated with this biomarker…

Attributes

Phase: Two
QA State: Under Review
Organ-specific information for this biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact the Informatics Center if you should have access to this biomarker.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact the Informatics Center if you should have access to this biomarker.

Version 5.0.2